Financial PerformanceCorMedix reported robust 1Q25 financial results with total revenues of $39.1M for DefenCath, reflecting growing, durable interest and adoption of DefenCath for infection prevention.
Growth PotentialDefenCath is well-positioned for growth based on achievable guidance, with potential drivers including new contracts and greater protocolization at current customers.
Market OutlookThe management raised the 1H outlook to the upper end of the $62M-$70M initial guide as inventory shuffle at the largest customer subsided.